Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

Background A consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO). Objective Since serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the assoc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Targeted oncology 2018-12, Vol.13 (6), p.795-800
Hauptverfasser: Fucà, Giovanni, Galli, Giulia, Poggi, Marta, Lo Russo, Giuseppe, Proto, Claudia, Imbimbo, Martina, Vitali, Milena, Ganzinelli, Monica, Lanti, Claudia, Molino, Giuliano, Stangoni, Fabiano, Zilembo, Nicoletta, de Braud, Filippo, Garassino, Marina Chiara, Signorelli, Diego
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background A consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO). Objective Since serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the association between low baseline serum sodium concentration (≤ 135 mEq/L) and clinical outcomes of patients with metastatic NSCLC treated with IO. Patients and Methods We included metastatic NSCLC patients treated with checkpoint inhibitors in our department from April 2013 to April 2018 with available baseline serum sodium concentration. Demographics, clinical and pathological characteristics were collected. Survival analyses were performed using the Kaplan-Meier method and the Cox proportional-hazards model. Results Of 197 patients included, 26 (13%) presented low baseline serum sodium concentration. Patients in the low sodium cohort experienced a poorer disease control rate (OR 0.36; 95% CI, 0.15–0.86; Wald test P = .02), median overall survival (OS) (2.8 vs. 11.6 months; HR 3.00; 95% CI, 1.80–4.80; P  
ISSN:1776-2596
1776-260X
DOI:10.1007/s11523-018-0599-5